148983-25-9

Basic information

• Product Name: Carbamic acid, [(2S)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(2S)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 148983-25-9
• Molecular Formula: C₈H₁₇NO₄
• Molecular Weight: 191.22488
• Product Categories: N-BOC
• Mol File: 148983-25-9.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 361.6±32.0 °C(Predicted)
• Appearance: /
• Density: 1.136±0.06 g/cm3(Predicted)
• PKA: 12.19±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(2S)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(2S)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(148983-25-9)
• EPA Substance Registry System: Carbamic acid, [(2S)-2,3-dihydroxypropyl]-, 1,1-dimethylethyl ester (9CI)(148983-25-9)

Safety Data

• Hazardous Substances Data: 148983-25-9(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 148982-76-7 tert-butyl N-(2-oxiranylmethyl)carbamate 
• 61278-21-5 (S)-3-Amino-1,2-propanediol 

Relevant articles and documents

Diversity oriented concise asymmetric synthesis of azasugars: A facile access to l-2,3-trans-3,4-cis-dihydroxyproline and (3S,5S)-3,4,5-trihydroxypiperidine

Diversity oriented concise asymmetric syntheses of l-2,3-trans-3,4-cis-dihydroxyproline and (3S,5S)-3,4,5-trihydroxypiperidine have been developed from (R)-glycidol. The key step of the synthesis is Sharpless asymmetric dihydroxylation on enantiomerically pure TBDMS protected allylic alcohol 14 which generates the triol intermediate 15 in excellent de. The (2R,3R,4S)-2,3-dihydroxypentanoate derivative 15 was subsequently converted to natural pyrrolidine azasugar 1 and non-natural piperidine azasugar 4 under cascade reaction conditions in good yields.

MACROCYCLIC COMPOUNDS FOR TREATING DISEASE

The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.

BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.